{"brief_title": "Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents", "brief_summary": "This study will evaluate the effectiveness of the medications, lithium (Eskalith\u00ae), valproate (Depakote\u00ae), and risperidone (Risperdal\u00ae) in treating children and adolescents with bipolar disorder or symptoms of mania.", "detailed_description": "Patients are randomly assigned to receive lithium (Eskalith), valproate (Depakote), or risperidone (Risperdal) for 8 to 16 weeks. They will have weekly visits to monitor their response to the medication. When the study is complete, care will be transferred to the child's treating psychiatrist.", "condition": "Bipolar Disorder", "intervention_type": "Drug", "intervention_name": "Risperidone", "description": "Titrated by weight until dose is 2.0 mg BID to 3.0 mg BID", "arm_group_label": "3", "other_name": "Risperdal", "criteria": "Inclusion Criteria: - DSM-IV criteria for bipolar I (manic or mixed) or mania for at least 4 weeks - CGAS less than or equal to 60 - Good physical health Exclusion Criteria: - Schizophrenia or any pervasive developmental disorder - Major medical or neurological disease - History of addiction to illicit substances or alcohol or drug abuse within the last 4 weeks - IQ less than 70 - Pregnancy or breast-feeding - Unacceptable methods of contraception - In-patient care at baseline", "gender": "All", "minimum_age": "6 Years", "maximum_age": "15 Years", "healthy_volunteers": "No", "id": "NCT00057681.xml"}